Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 3/20 | 0.41 |
| ▸ | GMNN | O75496 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14172957 | 1.00 | FAAH (0.43) | FAAHCES1BLMGMNNUSP2 | |
| SCHEMBL10341367 | 1.00 | FAAH (0.43) | FAAHCES1BLMGMNNUSP2 | |
| SCHEMBL10430273 | 1.00 | FAAH (0.43) | FAAHCES1BLMGMNNUSP2 | |
| SCHEMBL9226908 | 1.00 | FAAH (0.43) | FAAHCES1BLMGMNNUSP2 | |
| SCHEMBL10341365 | 1.00 | FAAH (0.43) | FAAHCES1BLMGMNNUSP2 | |
| SCHEMBL9226897 | 1.00 | FAAH (0.43) | FAAHCES1BLMGMNNUSP2 | |
| SCHEMBL4924476 | 0.98 | FAAH (0.44) | FAAHCES1BLMGMNNUSP2 | |
| SCHEMBL8380159 | 0.98 | FAAH (0.44) | FAAHCES1BLMGMNNUSP2 | |
| SCHEMBL9219367 | 0.98 | FAAH (0.44) | FAAHCES1BLMGMNNUSP2 | |
| SCHEMBL9220287 | 0.98 | FAAH (0.44) | FAAHCES1BLMGMNNUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0420987-A1 | Process for preparing fluoroalkyl derivatives | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1991-04-10 | — | — | EP | claimed |
| EP-3458037-B1 | FLUOROCHEMICAL TARGETED THERAPIES | MTM RES LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250269030-A1 | PHOTODYNAMIC COMPOSITIONS AND METHODS OF USE | MT RES LLC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250262332-A1 | FLUOROCHEMICAL TARGETED THERAPIES | MT RES LLC (US) | 2025-08-21 | — | — | US | disclosed |
| US-12239719-B2 | Fluorochemical targeted therapies | MT RESEARCH, LLC (US) | 2025-03-04 | — | — | US | disclosed |
| CN-112135603-B | Pharmaceutical composition comprising nebivolol | 诺瓦利克有限责任公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20230191096-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING SUBJECT IN HYPOXIC STATE DUE TO RESPIRATORY FAILURE, ETC. | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4151206-A1 | PHARMACEUTICAL COMPOSITION USED TO TREAT SUBJECT IN HYPOXIC STATE DUE TO RESPIRATORY FAILURE, ETC | National University Corporation Tokyo Medical and Dental University (JP) | 2023-03-22 | — | — | EP | disclosed |
| US-11576893-B2 | Pharmaceutical compositions comprising nebivolol | NOVALIQ GMBH (DE) | 2023-02-14 | — | — | US | disclosed |
| EP-3638643-B1 | PROCESS FOR THE PREPARATION OF SEMIFLUORINATED ALKANES USING GRIGNARD REAGENTS | NOVALIQ GMBH (DE) | 2023-01-18 | — | — | EP | disclosed |
| US-20210106558-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL | NOVALIQ GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| EP-3773469-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TIMOLOL | Novaliq GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| EP-3758676-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL | Novaliq GmbH (DE) | 2021-01-06 | — | — | EP | disclosed |
| CN-112135603-A | Pharmaceutical composition comprising nebivolol | 诺瓦利克有限责任公司 | 2020-12-25 | — | — | CN | disclosed |
| CN-111867560-A | Pharmaceutical composition comprising timolol | 诺瓦利克有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019185543-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TIMOLOL | NOVALIQ GMBH (DE) | 2019-10-03 | — | — | WO | disclosed |
| WO-2018215638-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZITHROMYCIN | NOVALIQ GMBH (DE) | 2018-11-29 | — | — | WO | disclosed |
| EP-0420987-B1 | Process for preparing fluoroalkyl derivatives | NIPPON OILS & FATS CO LTD (JP) | 1995-05-03 | — | — | EP | disclosed |
| US-5118879-A | Used in the synthesis of medicinal and agricultural chemicals and water- and oil-repellent agents | NIPPON OIL AND FATS CO., LTD. (JP) | 1992-06-02 | — | — | US | disclosed |
| EP-0420987-A1 | Process for preparing fluoroalkyl derivatives | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576893-B2 | Pharmaceutical compositions comprising nebivolol | ADRB1, ADRA1B, ADRB2 | FAAH 261/4885CES1 1210/4885BLM 2560/4885 |
| US-20210106558-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL | ADRB1, ADRA1B, ADRB2 | FAAH 261/4885CES1 1210/4885BLM 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.